Skip to main
LVTX
LVTX logo

LVTX Stock Forecast & Price Target

LVTX Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

LAVA Therapeutics NV is advancing its clinical-stage immuno-oncology platform focused on bispecific antibody development, which may revolutionize cancer treatment. The company recently announced a definitive agreement to acquire XOMA Royalty, a strategic move that underscores LAVA's commitment to enhancing its pipeline and financial positioning. This acquisition, alongside promising developments from its pipeline including LAVA-1266 and LAVA-1427, suggests strong future potential for the company's growth and value creation.

Bears say

LAVA Therapeutics NV has announced the discontinuation of its Phase 1 study of LAVA-1266, indicating a significant setback in its clinical development pipeline. The company's ongoing plans to wind down this program come amid a pending acquisition, raising concerns about its financial stability and future growth prospects. This situation has prompted a reevaluation of the company's valuation, resulting in a lowered price target, which reflects an overall negative outlook for LAVA's stock performance.

LVTX has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LAVA Therapeutics NV (LVTX) Forecast

Analysts have given LVTX a Hold based on their latest research and market trends.

According to 4 analysts, LVTX has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LAVA Therapeutics NV (LVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.